VEC Vectura Group Plc

TIDMVEC

RNS Number : 9997N

Vectura Group plc

27 May 2020

Share buyback programme

Chippenham, UK - 27 May 2020: Vectura Group plc (LSE: VEC) ("Vectura" or "the Company"), an industry-leading inhalation CDMO, today provides an update on the second GBP10 million tranche of its previously announced GBP20 million share buyback programme.

Vectura entered into an agreement with Numis Securities Limited ("Numis") on 26 May 2020 to enable Numis, acting as principal, to purchase ordinary shares of 0.0271 pence each in the Company ("Ordinary Shares") up to a maximum aggregate consideration of GBP10 million (the "Programme"). The agreement, which begins today and expires on 31 December 2020, authorises Numis to purchase the Ordinary Shares in accordance with the terms of the general authority expected to be granted to Vectura by its shareholders at the 2020 Annual General Meeting held today, 27 May 2020. Any purchase of Ordinary Shares pursuant to the Programme will be effected within certain pre-set parameters and Ordinary Shares that are purchased will be cancelled.

Numis will make its trading decisions in relation to the Programme independently of, and uninfluenced by, Vectura.

The Programme is expected to commence on 1 June 2020, and will be carried out on the London Stock Exchange and executed in accordance with Article 5(1) of Regulation (EU) No 596/2014, the Commission Delegated Regulation (EU) 2016/1052 and Chapter 12 of the Financial Conduct Authority's Listing Rules.

The Company will announce any market purchase of Ordinary Shares no later than 7.30 a.m. on the business day following the calendar day on which the purchase occurred. The purpose of the Programme is to reduce the share capital of the Company.

As at 27 May 2020, the total number of ordinary shares in the Company with voting rights is 604,290,969.

- Ends-

For more information, please contact:

Vectura Group plc

   Elizabeth Knowles - VP Investor Relations                          +44 (0)7767 160 565 
   David Ginivan - VP Corporate Communications                 +44 (0)7471 352 720 
   Consilium Strategic Communications                                 +44 (0)20 3709 5700 

Mary-Jane Elliott / Sue Stuart / David Daley

About Vectura

Vectura is a provider of innovative inhaled drug delivery solutions that enable partners to bring their medicines to patients. With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies.

Vectura has eleven key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com

Forward-looking statements

This press release contains forward-looking statements, including statements about the commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward looking statements, including: commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward looking statements, whether as a result of new information, future events or otherwise.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

POSUNORRRAUVUUR

(END) Dow Jones Newswires

May 27, 2020 02:00 ET (06:00 GMT)

Vectura (LSE:VEC)
Historical Stock Chart
From Mar 2024 to Apr 2024

Vectura (LSE:VEC)
Historical Stock Chart
From Apr 2023 to Apr 2024